HT
SPRY icon

Headlands Technologies’s ARS Pharmaceuticals SPRY Stock Holding History

Headlands Technologies’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$603K Buy
75,279
+27,073
+56% +$233K 0.06% 365
2026
Q1 		$387K Buy
+48,206
New +$462K 0.04% 431

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Headlands Technologies's SPRY Position: Q2 2026 in Review

Headlands Technologies increased its ARS Pharmaceuticals (SPRY) stake by 56% in Q2 2026, buying an estimated $233K and bringing the position to 75,279 shares worth $603K. The position accounts for 0.06% of the portfolio, ranked #365.

Headlands Technologies first reported a position in SPRY in Q1 2026 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Headlands Technologies held 75,279 shares of ARS Pharmaceuticals worth $603K as of Q2 2026.
  • Headlands Technologies bought 27,073 ARS Pharmaceuticals shares in Q2 2026, an estimated $233K.
  • ARS Pharmaceuticals made up 0.06% of Headlands Technologies's portfolio in Q2 2026, its #365 holding.
  • Headlands Technologies first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.